Home Latest Articles
Latest Articles
  • Yun ZHANG, Qi DING, Yang MENG, Shiyao HE, Wenting WU, Yan KANG
    Chinese Journal of Pharmaceuticals. 2026, 57(4): 467-474.

    To assess microbial contamination characteristics in cleanroom environments of medical device manufacturing and explore effective monitoring strategies, this study selected three 100 000-garde clean rooms from two enterprises in Jiangxi province. The airborne bacteria were sampled and analyzed using full-length 16S rRNA gene sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for microbial protein fingerprinting. A total of 42 strains of microorganisms were isolated and identified. The results showed that the dominant genera were Staphylococcus(21.4%), Moraxella(14.2%), and Micrococcus(11.9%), and three strains of fungi were detected. The microbial community composition differed significantly among different factory areas, and most strains were region-specific, reflecting the dependence of microbial contamination on environmental conditions.Among them, Moraxella osloensis(M. osloensis) was the only dominant strain found in all three factory areas. It might be carried by personnel, suggesting that the enterprises should enhance personnel hygiene and disinfection management. Further protein fingerprinting analysis of six M. osloensis strains revealed that although the overall spectra were highly consistent, strain-specific protein peaks were still present, indicating that this technique has certain limitations in strain discrimination. The combination of molecular biology and proteomics technologies can improve the accuracy of environmental microbial monitoring. It is recommended that relevant enterprises should establish a multi-point regular monitoring system, optimize disinfection strategies, and promote the construction of a localized protein fingerprint database to enhance the overall ability to control microbial contamination.

  • Xinyi LI, Shaoqing MA
    Chinese Journal of Pharmaceuticals. 2026, 57(4): 475-480.
  • Chao YANG
    Chinese Journal of Pharmaceuticals. 2026, 57(4): 481-486.
  • Yu WU, Fuchao CHEN, Minjing CAO, Haixia ZHENG, Lei YANG
    Chinese Journal of Pharmaceuticals. 2026, 57(4): 487-493.
  • Jianhui LIU, Yufeng MAO
    Chinese Journal of Pharmaceuticals. 2026, 57(4): 494-498.
  • Shuqi YIN, Ting PAN, Jun HE
    Chinese Journal of Pharmaceuticals. 2026, 57(3): 257-267.

    RNA-based therapeutics represent a pivotal modality in precision medicine, and their clinical advancement hinges on the development of highly efficient and safe delivery systems. Given their superior safety, substantial drug-loading capacity, and scalability for industrial production, non-viral delivery systems have become predominant in the field. This review systematically summarizes the approved RNA drugs and analyzes their core delivery strategies in detail. Furthermore, it discusses the key bottlenecks limiting the clinical translation of non-viral platforms, including low delivery efficiency, inefficient endosomal escape, short systemic circulation time, and insufficient extrahepatic targeting capabilities, as well as existing mitigating strategies, with the aim of promoting more effective clinical transformation of RNA therapeutics.

  • Jiao LU, Changhui ZHOU, Bin YANG, Yan CHANG
    Chinese Journal of Pharmaceuticals. 2026, 57(3): 268-275.

    Epigenetics refers to the study of heritable changes in gene expression that occur without alterations to the DNA base sequence, primarily through mechanisms such as DNA methylation, histone modification, and non-coding RNA. Traditional genotoxicity testing focuses mainly on damage to the DNA sequence itself, making it difficult to identify potential toxicity risks that do not involve sequence changes but may lead to long-term or transgenerational phenotypic effects. As research into epigenetic regulatory mechanism advances, the importance of epigenetics as a novel target for toxicity assessment has become increasingly evident. This article systematically reviews recently developed methods for detecting epigenetic alterations, including techniques for analyzing DNA methylation, histone post-translational modification, and non-coding RNA. It compares the principles, advantages, and limitations of these methods and discusses their applicability across different application scenarios, providing a reference for selecting appropriate detection strategies in drug safety evaluation and related toxicological studies.

  • Pingnan WAN, Xiang NIU, Jie WANG, Zengtao WANG, Tiantian WANG
    Chinese Journal of Pharmaceuticals. 2026, 57(3): 276-282.

    KSQ-4279(1), the first ubiquitin-specific protease 1(USP1) inhibitor to enter phase Ⅰ clinical trials, is being evaluated for the treatment of multiple cancers, including ovarian and triple-negative breast cancer. Due to its novel and unique structure, 1has emerged as a key lead compound for the design and scaffold modification of this class of inhibitors. Systematic modifications and structure-activity relationship analyses of the four structural units of 1have revealed the functional characteristics of each fragment. In recent years, structural modifications of 1have yielded numerous“me-too” candidates. This review summarizes the modification strategies and structure-activity relationship studies of 1, aiming to provide valuable insights and references for future research in this field.

  • Haibo WANG, Ansheng YU, Hongfu KUANG, Chenli XU, Fei WANG
    Chinese Journal of Pharmaceuticals. 2026, 57(3): 283-291.

    In order to effectively control the quality of bempedoic acid(1), seven related substances were synthesized, namely 2,2-dimethyl-7-(p-tolylthio)heptanoic acid(related substance A), (8R/S)-15-ethoxy-8-hydroxy-2,2,14,14-tetramethyl-15-oxopentadecanoic acid(related substance B), 8-oxo-2,2,14,14-tetramethylpentadecanedioic acid(related substance C),8,14-dihydroxy-2,2,20,20-tetramethylhenicosanedioic acid(related substance D), 2,2,8,8-tetramethylnonanedioic acid(related substance E), (7R/S,8R/S)-8-hydroxy-2,2,14,14-tetramethyl-7-(p-tolylthio)-pentadecanedioic acid(related substance F) and (8R/S)-8,15-dihydroxy-2,2,14,14-tetramethylpentadecanoic acid(related substance G). Among them, the related substances A and F and their synthetic routes were reported for the first time. The seven related substances were synthesized via short routes under mild reaction conditions, with purities of no less than 95%. Their structures were confirmed by 1H NMR,13 C NMR and HRMS. This paper could provide some references for the quality control of 1.

  • Naihua ZHANG, Shiguo ZHU, Tong LIU, Junhao JIA, Guimin ZHANG
    Chinese Journal of Pharmaceuticals. 2026, 57(3): 292-296.

    A new synthetic process of bilastine(1) has been reported. Commercially available 1-(2-ethoxyethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole(2) was reacted with 2-chloroethan-1-ol to afford 2-[1-(2-hydroxyethyl)piperidin-4-yl]-1-(2-ethoxyethyl)-1H-benzo[d]imidazole(3). Compound 3was transformed into 2-[1-(2-bromoethyl)piperidin-4-yl]-1-(2-ethoxyethyl)-1H-benzo[d]imidazole(4) by bromination reaction in the presence of N-bromosuccinimide/triphenylphosphine system. Bilastine methyl ester hydrochloride(6) was obtained through Nigishi cross-coupling reaction from 4and methyl 2-(4-bromophenyl)-2-methylpropanoate(5), followed by salification with hydrochloric acid. Finally, the target compound 1was obtained through hydrolysis reaction of 6and recrystallization from methanol. The total yield was 70.7% with a purity of 99.7%. The novel synthetic process has mild reaction conditions and simple operation, which makes it suitable for industrial production. The synthetic method for 6from 4and 5was reported for the first time.

News